We apologize for Proteopedia being slow to respond. For the past two years, a new implementation of Proteopedia has been being built. Soon, it will replace this 18-year old system. All existing content will be moved to the new system at a date that will be announced here.
User:Elizabeth Yowell/ SandboxFinal
From Proteopedia
(Difference between revisions)
| Line 15: | Line 15: | ||
===AHB2 and LCB1/LCB3 Specifically=== | ===AHB2 and LCB1/LCB3 Specifically=== | ||
| - | [[Image:ACB1_Methodology.png|400 px|left|thumb|The use of the Rosetta Blueprint | + | [[Image:ACB1_Methodology.png|400 px|left|thumb|The use of the Rosetta Blueprint protein design to create the AHB2 inhibitor.]] |
| + | [[Image:LCB1_Methodology.png|400 px|left|thumb|The use of the De Novo protein design to create the LCB1 and LCB3 inhibitors.]] | ||
Revision as of 20:32, 2 April 2025
Contents |
SARS CoV-2 Protein Inhibitors (AHB2 and LCB1/LCB3)
| |||||||||||
References
PDB Files
[1]https://www.rcsb.org/structure/7UHB
Student Contributors
- Giavanna Yowell
- Shea Bailey
- Matthew Pereira
